All In MedTech

FDA Clearance Tracker · P160048-S023

Eversense E3 Continuous Glucose Monitoring System (CGM System) - Entire System, Eversense E3 Sensor, Eversense E3 Insert

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 22, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 22, 2023

Approved

Time to decision

28 days

Received Feb 22, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P160048-S023
Device name
Eversense E3 Continuous Glucose Monitoring System (CGM System) - Entire System, Eversense E3 Sensor, Eversense E3 Insert
Applicant location
Germantown, MD
Received
Feb 22, 2023
Decided
Mar 22, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P160048

Device type

Device class
Class III

Every decision under product code QHJ

FDA's approval statement

As written in FDA's record.

Approval of the revised protocol for the post-approval study (PAS) protocol.

Source documents

Other decisions for Senseonics, Incorporated

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.